Nuclear Medicine，or Radiopharmaceuticals， are radioactive compounds administered to the patient, and monitored via specific imaging devices, for diagnosis and therapeutic purposes. It is composed of a radioisotope bond to an organic molecule. The organic molecule conveys the radioisotope to specific organs, tissues or cells. The radioisotope is selected for its properties. Radiopharmaceuticals are used in the field of nuclear medicine as radioactive tracers in medical imaging and in therapy for many diseases (for example, brachytherapy). Many radiopharmaceuticals use technetium-99m (Tc-99m) which has many useful properties as a gamma-emitting tracer nuclide.

The global Nuclear Medicine/Radiopharmaceutic market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Nuclear Medicine/Radiopharmaceutic volume and value at global level, regional level and company level. From a global perspective, this report represents overall Nuclear Medicine/Radiopharmaceutic market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:
GE Healthcare
Bracco Imaging
Mallinckrodt
Lantheus Medical Imaging
Bayer
Jubilant Pharma
Nordion
Eli Lilly
SIEMENS
China Isotope & Radiation
Yantai Dongcheng Biochemicals

Segment by Regions
North America
Europe
China
Japan

Segment by Type
Tc-99
I-123/131
In-111
Xe-133
Th-201
Ga-67
Other

Segment by Application
Diagnostic
Therapeutic